1. Home
  2. OXSQ vs MOLN Comparison

OXSQ vs MOLN Comparison

Compare OXSQ & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

HOLD

Current Price

$1.94

Market Cap

151.9M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.15

Market Cap

151.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXSQ
MOLN
Founded
2003
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
151.9M
151.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OXSQ
MOLN
Price
$1.94
$4.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
1.2M
5.9K
Earning Date
02-27-2026
03-05-2026
Dividend Yield
21.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,142,565.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.27
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.56
$3.36
52 Week High
$2.87
$5.35

Technical Indicators

Market Signals
Indicator
OXSQ
MOLN
Relative Strength Index (RSI) 62.11 49.36
Support Level $1.84 $3.97
Resistance Level $1.98 $4.27
Average True Range (ATR) 0.06 0.17
MACD 0.01 -0.00
Stochastic Oscillator 83.72 53.65

Price Performance

Historical Comparison
OXSQ
MOLN

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: